Skip to content
Open access

Neoadjuvant chemotherapy induces transient, regimen-specific immune–stromal reprogramming in pancreatic ductal adenocarcinoma

Sep 2026 · bioRxiv · 0 citations · 8 references
Biology

TL;DR

NAC dynamically reprograms the immune–stromal landscape of PDAC in a regimen- and timing-dependent manner, revealing a transient post-chemotherapy window of immune remodelling.

Abstract

Background Neoadjuvant chemotherapy (NAC) is increasingly incorporated into the management of pancreatic ductal adenocarcinoma (PDAC), yet how treatment regimen and timing reshape the tumour-immune microenvironment remains poorly defined. Methods Targeted immune transcriptomic profiling was performed using NanoString on spatially annotated tumour, stromal, and immune-enriched regions from resected PDAC specimens from 23 patients, including NAC-treated and treatment-naïve cohorts. Key findings were validated and spatially localised using Xenium in situ transcriptomics. Results NAC induced extensive transcriptional remodelling of the tumour microenvironment in a regimen- and time-dependent manner. Tumours resected shortly after FOLFIRINOX exhibited coordinated upregulation and strong spatial coupling of the CXCL12–CXCR4 axis. These correlations were attenuated or reversed at longer post-treatment intervals and following gemcitabine-based therapy. Disrupted stromal coordination of the CCL2–CCR2 axis further highlighted context-dependent effects of chemotherapy on chemokine signalling. Across regions, NT5E (CD73) expression inversely correlated with CD8A, consistent with spatially restricted T cell exclusion. Conclusions NAC dynamically reprograms the immune–stromal landscape of PDAC in a regimen- and timing-dependent manner, revealing a transient post-chemotherapy window of immune remodelling. The clinical significance of this phenomenon requires further investigation to determine whether temporally optimised integration of immunomodulatory and stroma-targeted therapies with NAC can improve patient outcomes. Graphical abstract

Read PDF

Similar papers

Review Open access Oct 2026

Tumor microenvironment-driven therapeutic resistance in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most treatment-refractory malignancies, with limited and often transient benefit from chemotherapy, targeted therapy, immunotherapy, and radiotherapy. Therapeutic resistance is increasingly recognized as an ecosystem-level process arising from reciprocal intera...

Hong-Jiao Li, Jia-Ning Cui, Xin Yang et al. · 0 citations
Open access Oct 2026

Spatial multi-omics reveals that CXCL10 enhances the response to nICT in surgically resectable esophageal squamous cell carcinoma

Neoadjuvant immune-chemotherapy (nICT) has transformed the treatment strategy for esophageal squamous cell carcinoma (ESCC), yet the molecular mechanisms underlying treatment response remain incompletely understood. To investigate these mechanisms, we jointly analyzed matched ESCC specimens obtained before and after...

Ye-Feng Shen, Yun-Lei Ma, Huan-Song Yang et al. · 0 citations
Open access Nov 2026

Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer.

Chemotherapy remains the backbone of neoadjuvant treatment for triple-negative breast cancer (TNBC), and response to chemotherapy strongly correlates with patient prognosis. However, predicting chemoresistance remains a major clinical challenge. To address this obstacle, we performed serial fine needle aspirations foll...

Amanda L. Rinkenbaugh, Gloria V. Echeverria, Jian-Su Shao et al. · 0 citations
Review Open access Sep 2026

Immuno-Oncology in Pancreatic Ductal Adenocarcinoma: Biological Rationale, Clinical Progress, and Future Directions

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies, characterised by rising incidence, poor long-term survival, and profound resistance to systemic therapy. Its poor prognosis reflects late diagnosis, early metastatic spread, and a uniquely desmoplastic, immunosuppressive tumour microe...

A. Lefas, H. Lote, I. Chau · 0 citations
Open access Oct 2026

Characterization of SPP1 + macrophages and their correlation with resistance to neoadjuvant chemotherapy in colorectal cancer liver metastasis

These findings position SPP1 + macrophages as central drivers of NAC resistance in CRLM and highlight the spatial immune barrier they create as a promising therapeutic target for overcoming chemoresistance and improving immunotherapy responses.

Jing-Zhi Tang, Wei-Jie Hao, Xi-Gan He et al. · 0 citations
Sep 2026

Abstract B096: Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer

It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.

Sarah Kang, M. Parikh, Leontios Pappas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.